早期使用丙戊酸钠对创伤性脑损伤后神经炎症影响的探索性研究

doi:10.7499/j.issn.1008-8830.2210136

摘要
图/表
参考文献(24)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (577 KB) [HTML]
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的研究早期使用丙戊酸钠对创伤性脑损伤（traumatic brain injury，TBI）后神经炎症的影响。方法前瞻性选取2021年8月—2022年8月在徐州医科大学附属徐州儿童医院接受诊治或体检的45例儿童为研究对象，其中包括15例健康体检儿童为健康对照组，30例TBI患儿采用随机数字表法分为丙戊酸钠组和常规组，每组15例。丙戊酸钠组在常规治疗基础上加丙戊酸钠，常规组在常规治疗基础上加等量5%葡萄糖溶液。检测健康对照组体检当天，TBI患儿入院第1天、第3天、第5天血清核苷酸结合寡聚化结构域样受体蛋白3（nucleotide-binding oligomerization domain-like receptor protein 3，NLRP3）、高迁移率族蛋白B1（high mobility group box protein 1，HMGB1）、肿瘤坏死因子-α（tumor necrosis factor-α，TNF-α）及白细胞介素-1β（interleukin-1β，IL-1β）浓度。评估出院2个月后TBI患儿格拉斯哥预后延伸评分。结果 TBI患儿第1天血清NLRP3、HMGB1、TNF-α和IL-1β浓度均显著高于健康对照组（P<0.017）；TBI患儿第5天NLRP3浓度高于第1、3天（P<0.017），第3、5天丙戊酸钠组NLRP3浓度低于常规组（P<0.05）；常规组第1、3、5天HMGB1浓度差异无统计学意义（P>0.017），丙戊酸钠组第5天HMGB1浓度低于第1、3天（P<0.017），第5天丙戊酸钠组HMGB1浓度低于常规组（P<0.05）；TBI患儿第1天TNF-α浓度低于第3、5天（P<0.017），第3、5天丙戊酸钠组TNF-α浓度低于常规组（P<0.05）；TBI患儿第3天IL-1β浓度高于第1、5天（P<0.017），第3、5天丙戊酸钠组IL-1β浓度低于常规组（P<0.05）；丙戊酸钠组出院2个月后格拉斯哥预后延伸评分高于常规组（P<0.05）。结论早期使用丙戊酸钠可以减少TBI患儿神经炎症因子的释放，改善患儿预后。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	柳智
	朱磊
	盛利平
	黄卿琛
	钱同
	祁伯祥

关键词 ：创伤性脑损伤, 神经炎症, 丙戊酸钠, 儿童

Abstract：Objective To study the effect of early use of sodium valproate on neuroinflammation after traumatic brain injury (TBI). Methods A total of 45 children who visited in Xuzhou Children's Hospital Affiliated to Xuzhou Medical University from August 2021 to August 2022 were enrolled in this prospective study, among whom 15 healthy children served as the healthy control group, and 30 children with TBI were divided into a sodium valproate treatment group and a conventional treatment group using a random number table (n=15 each). The children in the sodium valproate treatment group were given sodium valproate in addition to conventional treatment, and those in the conventional group were given an equal volume of 5% glucose solution in addition to conventional treatment. The serum concentrations of nucleotide-binding oligomerization domain-like receptor protein 3(NLRP3), high-mobility group box 1 (HMGB1), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β) were measured in the healthy control group on the day of physical examination and in the children with TBI on days 1, 3, and 5 after admission. Glasgow Outcome Scale-Extended (GOS-E) score was evaluated for the children with TBI 2 months after discharge. Results Compared with the healthy control group, the children with TBI had significantly higher serum concentrations of NLRP3, HMGB1, TNF-α, and IL-1β on day 1 after admission (P<0.017). The concentration of NLRP3 on day 5 after admission was significantly higher than that on days 1 and 3 after admission in the children with TBI (P<0.017). On days 3 and 5 after admission, the sodium valproate treatment group had a significantly lower concentration of NLRP3 than the conventional treatment group (P<0.05). For the conventional treatment group, there was no significant difference in the concentration of HMGB1 on days 1, 3, and 5 after admission (P>0.017), while for the sodium valproate treatment group, the concentration of HMGB1 on day 5 after admission was significantly lower than that on days 1 and 3 after admission (P<0.017). On day 5 after admission, the sodium valproate treatment group had a significantly lower concentration of HMGB1 than the conventional treatment group (P<0.05). For the children with TBI, the concentration of TNF-α on day 1 after admission was significantly lower than that on days 3 and 5 after admission (P<0.017). On days 3 and 5 after admission, the sodium valproate treatment group had a significantly lower concentration of TNF-α than the conventional treatment group (P<0.05). The concentration of IL-1β on day 3 after admission was significantly lower than that on days 1 and 5 after admission (P<0.017) in the children with TBI. On days 3 and 5 after admission, the sodium valproate treatment group had a significantly lower concentration of IL-1β than the conventional treatment group (P<0.05). The GOS-E score was significantly higher in the sodium valproate treatment group than that in the conventional treatment group 2 months after discharge (P<0.05). Conclusions Early use of sodium valproate can reduce the release of neuroinflammatory factors and improve the prognosis of children with TBI.

Key words： Traumatic brain injury Neuroinflammation Sodium valproate Child

收稿日期: 2022-10-28

基金资助:江苏省妇幼健康科研项目（F201851）。

通讯作者: 祁伯祥，男，主任医师。Email：qiboxiang76@163.com。 E-mail: qiboxiang76@163.com

作者简介: 柳智，男，硕士研究生；

引用本文:

柳智,朱磊,盛利平等. 早期使用丙戊酸钠对创伤性脑损伤后神经炎症影响的探索性研究[J]. 中国当代儿科杂志, 2023, 25(3): 253-258.

LIU Zhi,ZHU Lei,SHENG Li-Ping et al. A pilot study on the effects of early use of valproate sodium on neuroinflammation after traumatic brain injury[J]. CJCP, 2023, 25(3): 253-258.

链接本文:

http://www.zgddek.com/CN/10.7499/j.issn.1008-8830.2210136 或 http://www.zgddek.com/CN/Y2023/V25/I3/253

	Menon DK, Schwab K, Wright DW, et al. Position statement: definition of traumatic brain injury[J]. Arch Phys Med Rehabil, 2010, 91(11): 1637-1640. PMID: 21044706. DOI: 10.1016/j.apmr.2010.05.017.
	Dewan MC, Mummareddy N, Wellons JC, et al. Epidemiology of global pediatric traumatic brain injury: qualitative review[J]. World Neurosurg, 2016, 91: 497-509.e1. PMID: 27018009. DOI: 10.1016/j.wneu.2016.03.045.
	Yi JH, Hazell AS. Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury[J]. Neurochem Int, 2006, 48(5): 394-403. PMID: 16473439. DOI: 10.1016/j.neuint.2005.12.001.
	Werner C, Engelhard K. Pathophysiology of traumatic brain injury[J]. Br J Anaesth, 2007, 99(1): 4-9. PMID: 17573392. DOI: 10.1093/bja/aem131.
	Prins M, Greco T, Alexander D, et al. The pathophysiology of traumatic brain injury at a glance[J]. Dis Model Mech, 2013, 6(6): 1307-1315. PMID: 24046353. PMCID: PMC3820255. DOI: 10.1242/dmm.011585.
	Chang P, Williams AM, Bhatti UF, et al. Valproic acid and neural apoptosis, inflammation, and degeneration 30 days after traumatic brain injury, hemorrhagic shock, and polytrauma in a swine model[J]. J Am Coll Surg, 2019, 228(3): 265-275. PMID: 30639301. PMCID: PMC6589830. DOI: 10.1016/j.jamcollsurg.2018.12.026.
	Liu Z, Li Y, Chong W, et al. Creating a prosurvival phenotype through a histone deacetylase inhibitor in a lethal two-hit model[J]. Shock, 2014, 41(2): 104-108. PMID: 24430491. PMCID: PMC4822203. DOI: 10.1097/SHK.0000000000000074.
	Ying GY, Jing CH, Li JR, et al. Neuroprotective effects of valproic acid on blood-brain barrier disruption and apoptosis-related early brain injury in rats subjected to subarachnoid hemorrhage are modulated by heat shock protein 70/matrix metalloproteinases and heat shock protein 70/AKT pathways[J]. Neurosurgery, 2016, 79(2): 286-295. PMID: 27244466. DOI: 10.1227/NEU.0000000000001264.
	Kochanek PM, Tasker RC, Carney N, et al. Guidelines for the management of pediatric severe traumatic brain injury, third edition: update of the Brain Trauma Foundation Guidelines, executive summary[J]. Neurosurgery, 2019, 84(6): 1169-1178. PMID: 30822776. DOI: 10.1093/neuros/nyz051.
	10 董宇为, 夏学巍, 冯波, 等. 丙戊酸钠对重型颅脑损伤患者的神经保护作用及癫痫预防效果的临床观察[J]. 医学综述, 2018, 24(20): 4137-4141. DOI: 10.3969/j.issn.1006-2084.2018.20.034.
	11 廖爱玲, 王岩, 兰俊英, 等. 丙戊酸钠通过激活核因子κB（NF-B）通路引起大鼠HAPI小胶质细胞炎症反应[J]. 细胞与分子免疫学杂志, 2021, 37(5): 421-426. DOI: 10.13423/j.cnki.cjcmi.009193.
	Wat R, Mammi M, Paredes J, et al. The effectiveness of antiepileptic medications as prophylaxis of early seizure in patients with traumatic brain injury compared with placebo or no treatment: a systematic review and meta-analysis[J]. World Neurosurg, 2019, 122: 433-440. PMID: 30465951. DOI: 10.1016/j.wneu.2018.11.076.
	Vezzani A, Balosso S, Ravizza T. Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy[J]. Nat Rev Neurol, 2019, 15(8): 459-472. PMID: 31263255. DOI: 10.1038/s41582-019-0217-x.
	Capizzi A, Woo J, Verduzco-Gutierrez M. Traumatic brain injury: an overview of epidemiology, pathophysiology, and medical management[J]. Med Clin North Am, 2020, 104(2): 213-238. PMID: 32035565. DOI: 10.1016/j.mcna.2019.11.001.
	Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use[J]. J Neurotrauma, 1998, 15(8): 573-585. PMID: 9726257. DOI: 10.1089/neu.1998.15.573.
	Dahl HM, Andelic N, L?vstad M, et al. Epidemiology of traumatic brain injury in children 15 years and younger in South-Eastern Norway in 2015-16. Implications for prevention and follow-up needs[J]. Eur J Paediatr Neurol, 2021, 31: 70-77. PMID: 33647532. DOI: 10.1016/j.ejpn.2021.02.002.
	Jiang JY, Gao GY, Feng JF, et al. Traumatic brain injury in China[J]. Lancet Neurol, 2019, 18(3): 286-295. PMID: 30784557. DOI: 10.1016/S1474-4422(18)30469-1.
	Loane DJ, Faden AI. Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies[J]. Trends Pharmacol Sci, 2010, 31(12): 596-604. PMID: 21035878. PMCID: PMC2999630. DOI: 10.1016/j.tips.2010.09.005.
	Wu H, Zheng J, Xu S, et al. Mer regulates microglial/macrophage M1/M2 polarization and alleviates neuroinflammation following traumatic brain injury[J]. J Neuroinflammation, 2021, 18(1): 2. PMID: 33402181. PMCID: PMC7787000. DOI: 10.1186/s12974-020-02041-7.
	Witcher KG, Bray CE, Chunchai T, et al. Traumatic brain injury causes chronic cortical inflammation and neuronal dysfunction mediated by microglia[J]. J Neurosci, 2021, 41(7): 1597-1616. PMID: 33452227. PMCID: PMC7896020. DOI: 10.1523/JNEUROSCI.2469-20.2020.
	Yu Q, Zhao T, Liu M, et al. Targeting NLRP3 inflammasome in translational treatment of nervous system diseases: an update[J]. Front Pharmacol, 2021, 12: 707696. PMID: 34526897. PMCID: PMC8435574. DOI: 10.3389/fphar.2021.707696.
	Karki R, Kanneganti TD. Diverging inflammasome signals in tumorigenesis and potential targeting[J]. Nat Rev Cancer, 2019, 19(4): 197-214. PMID: 30842595. PMCID: PMC6953422. DOI: 10.1038/s41568-019-0123-y.
	Manivannan S, Marei O, Elalfy O, et al. Neurogenesis after traumatic brain injury—the complex role of HMGB1 and neuroinflammation[J]. Neuropharmacology, 2021, 183: 108400. PMID: 33189765. DOI: 10.1016/j.neuropharm.2020.108400.
	Paudel YN, Angelopoulou E, Piperi C, et al. HMGB1-mediated neuroinflammatory responses in brain injuries: potential mechanisms and therapeutic opportunities[J]. Int J Mol Sci, 2020, 21(13): 4609. PMID: 32610502. PMCID: PMC7370155. DOI: 10.3390/ijms21134609.